The U.S. Food and Drug Administration has approved a new breast cancer drug from Celcuity for adults with advanced HR+/HER2- breast cancer. The drug, a targeted therapy, is intended for patients whose disease has progressed after prior endocrine therapy. According to the company’s announcement, the approval was based on a late-stage clinical trial that showed the drug significantly delayed tumor growth compared to standard treatment.

Key Takeaways

  • The FDA approved Celcuity’s drug for advanced HR+/HER2- breast cancer, a common subtype.
  • The treatment is a combination of a CDK4/6 inhibitor and an endocrine therapy.
  • Clinical trial data showed improved progression-free survival over standard care.
  • The approval offers a new option for patients whose cancer has progressed after initial treatments.

What Is the New Celcuity Drug?

The newly approved drug is a combination therapy that pairs a CDK4/6 inhibitor with an endocrine therapy. CDK4/6 inhibitors are a class of drugs that block enzymes involved in cell division, slowing the growth of cancer cells. The drug is designed for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer, which accounts for about 70% of all breast cancer cases.

Celcuity’s drug is administered orally and is intended for use after patients have already received endocrine therapy, which is a standard first-line treatment for this cancer type. The company has not yet announced a brand name for the drug, but it is being referred to as a next-generation CDK4/6 inhibitor in industry reports.

Clinical Trial Results

The FDA’s decision was supported by data from a Phase 3 clinical trial, as reported by the company. The trial enrolled patients with advanced HR+/HER2- breast cancer who had previously been treated with endocrine therapy. Participants were randomly assigned to receive either Celcuity’s drug plus an endocrine therapy or a placebo plus standard endocrine therapy.

Results showed that patients who received Celcuity’s drug had a statistically significant improvement in progression-free survival, meaning their cancer took longer to worsen compared to the control group. The company did not release overall survival data at the time of the approval announcement, but stated that the trial is ongoing and final results are expected later. Common side effects reported in the trial included fatigue, nausea, and low blood cell counts, which are typical for this class of drugs.

How Does This Compare to Existing Treatments?

Several CDK4/6 inhibitors are already approved for HR+/HER2- breast cancer, including palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Celcuity’s drug is considered a next-generation option that may offer a different safety profile or dosing schedule, according to the company. However, head-to-head comparisons with existing drugs have not been published, and it is not yet clear how the new drug will fit into clinical practice.

Experts quoted in the original report noted that the approval adds another tool for oncologists, particularly for patients who have progressed on earlier CDK4/6 inhibitors. The drug’s exact role will depend on factors such as side effects, cost, and insurance coverage.

What This Means for Patients

For patients with advanced HR+/HER2- breast cancer, the approval provides a new treatment option after standard therapies have stopped working. The drug is expected to be available by prescription in the coming weeks, and Celcuity has stated it will work with insurers to secure coverage. Patients should discuss with their oncologist whether this drug is appropriate for their specific cancer history and overall health.

It is important to note that the drug is not a cure but a treatment aimed at controlling the disease and extending the time before cancer progression. As with any cancer therapy, side effects and individual response will vary.

Frequently Asked Questions

Who is eligible for Celcuity’s new breast cancer drug?

The drug is approved for adults with advanced or metastatic HR+/HER2- breast cancer whose disease has progressed after prior endocrine therapy. Eligibility will be determined by a physician based on tumor type, previous treatments, and overall health.

What are the common side effects of this drug?

Based on clinical trial data, common side effects include fatigue, nausea, diarrhea, and low blood cell counts such as neutropenia. Patients should report any severe or persistent side effects to their healthcare provider.

How does this drug differ from other CDK4/6 inhibitors?

Celcuity’s drug is a next-generation CDK4/6 inhibitor that may have a different dosing schedule and side effect profile compared to older drugs like Ibrance or Kisqali. However, no direct comparison trials have been completed, so differences in effectiveness are not yet known.

This article is based on reporting from BioPharma Dive and the company’s announcement. Always consult a medical professional for personalized health advice.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.